137863-89-9 (缬沙坦烃化物,(S)-Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-methylbutanoate)

缬沙坦烃化物;N-[(2'-氰基-1,1'-联苯-4-基)甲基]-L-缬氨酸甲酯;N-[(2鈥?-Cyano-(1,1鈥?-biphenyl)-4-yl)methyl)]valine methyl ester;缬沙坦烃化物盐酸盐;

(S)-Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-methylbutanoate;N-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-L-valine methyl ester;L-Valine,N-[(2’-cyanol[1,1’-biphenyl]-4-yl)methyl],methyl easter;N-[(2’-CYANO-(1,1’-BIPHENYL)-4-YL) METHYL )] VALINE, METHYL ESTER, HCL;N-[(2-cyano (1, 1bp)-4-yl) methyl] valineMethylester;methyl (2S)-2-[[4-(2-cyanophenyl)phenyl]methylamino]-3-methylbutanoate;13EG6HX8ND;(S)-Methyl2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-methylbutanoate;AKOS015850911;137863-89-9;(S)-METHYL 2-((2'-CYANOBIPHENYL-4-YL)METHYLAMINO)-3-METHYLBUTANOATE;A886380;N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methylester;Valsartan impurity D;METHYL N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINATE;Valsartan impurity D [USP-MC];N-((2'-Cyano(1,1'-biphenyl)-4-yl)methyl)-L-valine methyl ester;DTXSID50587775;Methyl N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-L-valinate;Q27251511;methyl ((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-L-valinate;N-[(2'-cyanobiphenyl-4-yl) methyl]-(L)-valine methyl ester;UNII-13EG6HX8ND;L-Valine, N-((2'-cyano(1,1'-biphenyl)-4-yl)methyl)-, methyl ester;N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester;ZQHINOUCNQKQEV-IBGZPJMESA-N;SCHEMBL2174;N-[(2'-Cyano[1,1-biphenyl]-4-yl)methyl]-L-valine methylester;N-[(2'-Cyano-(1,1'-biphenyl)-4-yl)methyl)]valine methyl ester;METHYL (2S)-2-[({2'-CYANO-[1,1'-BIPHENYL]-4-YL}METHYL)AMINO]-3-METHYLBUTANOATE;

MFCD08436153

ZQHINOUCNQKQEV-IBGZPJMESA-N

1S/C20H22N2O2/c1-14(2)19(20(23)24-3)22-13-15-8-10-16(11-9-15)18-7-5-4-6-17(18)12-21/h4-11,14,19,22H,13H2,1-3H3/t19-/m0/s1

O(C)C([C@H](C(C)C)NCC1C=CC(C2C=CC=CC=2C#N)=CC=1)=O

2926909090